Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cancer discovery

Showing results (1091-1100 of 4,265) with videos related to

Pageof 427
Sort By:
Cancer Discovery|March 5, 2016
UK Groups Plan Cancer Research HubJanet Colwell
Cancer Discovery|May 23, 2012
ALKoma: a cancer subtype with a shared targetHiroyuki Mano
Cancer Discovery|December 28, 2014
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanomaBenchun Miao, Zhenyu Ji, Li Tan, et al.
Cancer Discovery|November 23, 2013
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionHubing Shi, Aayoung Hong, Xiangju Kong, et al.
Cancer Discovery|November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibitionNikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
Cancer Discovery|July 9, 2014
EGFR inhibitors may induce tumor stemness
Cancer Discovery|July 9, 2014
Gene deletion speeds mutation rate
Cancer Discovery|July 9, 2014
NIH program to sequence 1,000 exomes
Cancer Discovery|July 9, 2014
A MYOD1 mutation cooperates with PI3K pathway activation in ERMS
Cancer Discovery|July 9, 2014
New guidelines for HER2+ breast cancer
Pageof 427

Showing results (1091-1100 of 4,265) with videos related to

Sort By:
Pageof 427
Cancer Discovery|March 5, 2016
UK Groups Plan Cancer Research HubJanet Colwell
Cancer Discovery|May 23, 2012
ALKoma: a cancer subtype with a shared targetHiroyuki Mano
Cancer Discovery|December 28, 2014
EPHA2 is a mediator of vemurafenib resistance and a novel therapeutic target in melanomaBenchun Miao, Zhenyu Ji, Li Tan, et al.
Cancer Discovery|November 23, 2013
A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibitionHubing Shi, Aayoung Hong, Xiangju Kong, et al.
Cancer Discovery|November 23, 2013
MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibitionNikhil Wagle, Eliezer M Van Allen, Daniel J Treacy, et al.
Cancer Discovery|July 9, 2014
EGFR inhibitors may induce tumor stemness
Cancer Discovery|July 9, 2014
Gene deletion speeds mutation rate
Cancer Discovery|July 9, 2014
NIH program to sequence 1,000 exomes
Cancer Discovery|July 9, 2014
A MYOD1 mutation cooperates with PI3K pathway activation in ERMS
Cancer Discovery|July 9, 2014
New guidelines for HER2+ breast cancer
Pageof 427